Stockreport

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

ProMIS Neurosciences Inc. - Common Shares  (PMN) 
PDF Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease   Six-month Interim Result [Read more]